MY209059A - Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone - Google Patents

Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone

Info

Publication number
MY209059A
MY209059A MYPI2022001012A MYPI2022001012A MY209059A MY 209059 A MY209059 A MY 209059A MY PI2022001012 A MYPI2022001012 A MY PI2022001012A MY PI2022001012 A MYPI2022001012 A MY PI2022001012A MY 209059 A MY209059 A MY 209059A
Authority
MY
Malaysia
Prior art keywords
ophthalmic composition
aqueous ophthalmic
polyvinylpyrrolidone
diquafosol
salt
Prior art date
Application number
MYPI2022001012A
Inventor
Kamimura Asuka
Momokawa Yusuke
Endo Kenichi
Morishima Kenji
Asada Hiroyuki
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY209059A publication Critical patent/MY209059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 3% (w/v), polyvinylpyrrolidone having a K value of 90, and silver nitrate, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 3% (w/v), polyvinylpyrrolidone, and silver nitrate, the aqueous ophthalmic composition being used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time, wherein the aqueous ophthalmic composition has a viscosity at 25C of 3 to 30 mPas.
MYPI2022001012A 2019-08-27 2020-08-25 Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone MY209059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019154525 2019-08-27
PCT/JP2020/031917 WO2021039748A1 (en) 2019-08-27 2020-08-25 Diquafosol or salt thereof, and aqueous ophthalmic composition containing polyvinylpyrrolidone

Publications (1)

Publication Number Publication Date
MY209059A true MY209059A (en) 2025-06-18

Family

ID=74685901

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022001012A MY209059A (en) 2019-08-27 2020-08-25 Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone

Country Status (7)

Country Link
JP (3) JP6966667B2 (en)
KR (2) KR102656181B1 (en)
CN (2) CN114286670B (en)
MY (1) MY209059A (en)
PH (1) PH12022550474A1 (en)
TW (1) TWI848171B (en)
WO (1) WO2021039748A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP6966667B2 (en) * 2019-08-27 2021-11-17 参天製薬株式会社 Aqueous ophthalmic composition containing diquafosol or a salt thereof, and polyvinylpyrrolidone.
JP7175431B1 (en) 2021-03-30 2022-11-18 千寿製薬株式会社 Suspension containing heterocyclideneacetamide derivative
CN114646705A (en) * 2022-03-22 2022-06-21 武汉绿合医药科技有限公司 Method for detecting content of related substances in diquafosol sodium eye drops
JP2024043685A (en) * 2022-09-20 2024-04-02 参天製薬株式会社 Method for suppressing a decrease in pH of an ophthalmic composition containing diquafosol or a salt thereof
JP7245383B1 (en) 2022-09-20 2023-03-23 参天製薬株式会社 Method for Suppressing Decrease in pH of Ophthalmic Composition Containing Diquafosol or Its Salt
KR20250160050A (en) 2024-05-03 2025-11-11 삼천당제약주식회사 A pharmaceutical composition with improved physicochemical properties for preventing or treating dry eye syndrome
CN119970633A (en) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 Diquafosol sodium eye drops and preparation method thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0365270A (en) 1989-07-31 1991-03-20 Kanzaki Paper Mfg Co Ltd Manufacture of coated sheet
JPH0365270U (en) 1989-10-31 1991-06-25
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
KR100549904B1 (en) * 1996-03-27 2006-05-16 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 A pharmaceutical composition for treating ciliary dyskinesia, containing uridinde triphosphate and related compounds
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
WO2001047532A1 (en) * 1999-12-27 2001-07-05 Santen Pharmaceutical Co., Ltd. System for stabilizing lacrimal fluid layer
AU2001260643B9 (en) * 2000-05-30 2006-10-19 Merck Sharp & Dohme Corp. Ectocornea extension promoters
KR101389300B1 (en) * 2005-02-14 2014-04-25 존슨 앤드 존슨 비젼 케어, 인코포레이티드 A method of producing ophthalmic lenses, an ophthalmic device, and a contact lens
CA2810481C (en) * 2010-09-10 2018-06-19 Santen Pharmaceutical Co., Ltd. Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
AU2011350762B2 (en) * 2010-12-28 2017-04-06 Santen Pharmaceutical Co., Ltd. Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate
KR20120077080A (en) 2010-12-30 2012-07-10 동우 화인켐 주식회사 Optical film and backlight unit using the same
US20160213708A1 (en) * 2012-01-08 2016-07-28 Medicure Technologies Ltd. Ophthalmic composition
MY169816A (en) * 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
JP2015032653A (en) 2013-08-01 2015-02-16 株式会社東芝 Solid state imaging apparatus
JP6267003B2 (en) 2014-02-27 2018-01-24 参天製薬株式会社 Tear secretion promoter characterized by combining diquafosol or a salt thereof and rebamipide or a salt thereof
EP3139903B1 (en) * 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
EA034517B1 (en) * 2014-12-25 2020-02-17 Сантен Фармасьютикал Ко., Лтд. Aqueous ophthalmic solution
WO2016195072A1 (en) * 2015-06-05 2016-12-08 参天製薬株式会社 Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
CN107837276A (en) * 2016-09-19 2018-03-27 刘力 The pharmaceutical composition being locally administered
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP6966667B2 (en) * 2019-08-27 2021-11-17 参天製薬株式会社 Aqueous ophthalmic composition containing diquafosol or a salt thereof, and polyvinylpyrrolidone.

Also Published As

Publication number Publication date
WO2021039748A1 (en) 2021-03-04
KR20220052971A (en) 2022-04-28
JP2025031918A (en) 2025-03-07
JPWO2021039748A1 (en) 2021-09-30
JP2022003099A (en) 2022-01-11
CN117771172A (en) 2024-03-29
KR102656181B1 (en) 2024-04-08
PH12022550474A1 (en) 2023-03-06
TWI848171B (en) 2024-07-11
JP7902251B2 (en) 2026-08-07
JP6966667B2 (en) 2021-11-17
TW202122094A (en) 2021-06-16
CN114286670A (en) 2022-04-05
JP7614069B2 (en) 2025-01-15
KR20240049646A (en) 2024-04-16
CN114286670B (en) 2024-01-16

Similar Documents

Publication Publication Date Title
PH12022550474A1 (en) Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone
MX2022014313A (en) Formulations for oral administration of active agents with controlled absorption profile.
CL2018000033A1 (en) Composition to uncover a blocked nose that has antiviral activity.
TW201613588A (en) Ophthalmic composition
MY192577A (en) Ophthalmic solution comprising epinastine
UY36542A (en) PHARMACEUTICAL FORMULATIONS FOR ANTI-TNF-ALFA ANTIBODIES
PH12019501017A1 (en) Sgc stimulators
JP2017002035A5 (en)
AR105199A1 (en) Aqueous ophthalmic solutions
MY185334A (en) Glucagon derivatives with improved stability
JP2017502074A5 (en)
MX2020006309A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis.
HRP20180468T1 (en) NEW INSULIN ANALOG DERIVATIVE
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
JP2022003099A5 (en)
MX2018005028A (en) Skin care composition and method thereof.
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases
MX2020001084A (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases.
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
SG11201901617PA (en) Azole compound ophthalmic preparation
EP3295932A3 (en) Stable odf composition containing hardly soluble therapeutic agent
NZ602126A (en) Ophthalmic Solution for Treating Ocular Infection Comprising Levofloxacin or Salt Thereof or Solvate of the Same, Method for Treating Ocular Infection, Levofloxacin or Salt Thereof or Solvate of the Same, and Use Thereof
WO2018230858A3 (en) PHARMACEUTICAL COMPOSITION CONTAINING GLY-THYMOSIN β4 (GLY-Tβ4) FOR TREATMENT OF DRY EYE
BR112019004838A2 (en) treatment of non-hodgkin's lymphoma using lilotomab and 177lu-lilotomab satetraxetan